Clinical Trials on Leukemia, Myeloid, Chronic-Phase in Argentina

Total 60 results

Takeda

Active, not recruiting

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

Myeloid Leukemia, Chronic, Chronic Phase

United States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
Novartis Pharmaceuticals

Terminated

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) (TOPS)

Leukemia, Myeloid, Chronic Phase

United States, Argentina, Italy, Canada, Australia, Brazil
Bristol-Myers Squibb

Completed

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia

Netherlands, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Singapore, Taiwan, United Kingdom, France, Korea, Republic of, Philippines, Sweden, Thailand, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzer...
Bristol-Myers Squibb
PPD; ICON Clinical Research; Q2 Solutions; Molecular MD; MultiPharma; Steering Committee and other collaborators

Completed

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

Chronic Phase Chronic Myeloid Leukemia

Italy, Thailand, United States, Belgium, Czechia, Hungary, Argentina, Austria, Brazil, Canada, China, France, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Myeloid Leukemia, Chronic, Chronic-Phase

United States, Australia, France, Germany, Italy, Korea, Republic of, Sweden, Taiwan, Spain, Austria, Denmark, Belgium, Canada, Ireland, Switzerland, Netherlands, Peru, United Kingdom, South Africa, Argentina, Philippines, Singapore, Russian Federation and more
Bristol-Myers Squibb

Active, not recruiting

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Leukemia

France, India, United States, Canada, Spain, Italy, Mexico, South Africa, United Kingdom, Korea, Republic of, Russian Federation, Australia, Argentina, Germany, Brazil, Netherlands, Romania, Singapore
Bristol-Myers Squibb

Completed

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myeloid Leukemia, Chronic, Accelerated Phase

Australia, Canada, France, Germany, Italy, Korea, Republic of, Taiwan, Thailand, United States, Spain, Austria, Denmark, Belgium, Sweden, Switzerland, Netherlands, Peru, South Africa, Philippines, Singapore, Russian Federation, Br... and more
Fundaleu

Recruiting

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (AST)

CML

Argentina
Grupo Argentino de Tratamiento de la Leucemia Aguda

Recruiting

RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.

Acute Myeloid Leukemia, Adult

Argentina
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Netherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Singapore, France, Germany, United Arab Emirates, Greece, Italy, Czechia, Hungary, United States, India, Oman, Malaysia, Korea, Republic of, Turkey, Bulgaria, Canada, Slovakia, United Kingdom, Argentina, Jordan, Romania, South Africa and more
Bristol-Myers Squibb

Completed

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

Myeloid Leukemia, Chronic

Germany, India, Japan, Korea, Republic of, Turkey, Chile, China, Spain, Australia, France, Poland, Mexico, Colombia, Belgium, Austria, Italy, Peru, Greece, Brazil, Czech Republic, Hungary, Russian Federation, Netherlands, Argentina, Den... and more
Pfizer

Completed

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Chronic Myeloid Leukemia

United States, Canada, Spain, China, Australia, Singapore, Korea, Republic of, France, Hong Kong, Netherlands, Turkey, Poland, Japan, United Kingdom, Argentina, Colombia, Hungary, Russian Federation, South Africa, Belgium, Brazil, Chil... and more
Grupo Argentino de Tratamiento de la Leucemia Aguda

Recruiting

RWE of 1st Line Treatment With ATO/ATRA for Adult APL

Promyelocytic Leukemia, Adult Acute

Argentina
Novartis Pharmaceuticals

Active, not recruiting

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)

Chronic Myeloid Leukemia

Japan, Germany, Canada, Australia, France, Israel, Spain, United States, Greece, United Kingdom, Korea, Republic of, Brazil, Russian Federation, Argentina, Poland, Singapore, Belgium, Mexico
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (ENESTxtnd)

Chronic Myeloid Leukemia

Canada, Egypt, Saudi Arabia, Australia, Lebanon, South Africa, Israel, Russian Federation, Brazil, Thailand, Malaysia, Argentina, Taiwan, India, Oman, United Arab Emirates, Tunisia, Mexico, Algeria
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
Pfizer

Completed

Latin American Real-world Study in Acute Leukemia (LOYAL)

Acute Myeloid Leukemia | Acute Lymphoid Leukemia

Argentina, Brazil, Colombia, Chile
Hoffmann-La Roche

Completed

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Chronic Lymphocytic Leukemia

Argentina
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Chronic Myeloid Leukemia

United States, Spain, Australia, Canada, Hong Kong, Singapore, United Kingdom, Germany, Netherlands, Chile, India, South Africa, Sweden, Peru, Argentina, Italy, Austria, Colombia, Brazil, China, Finland, Hungary, Korea, Republic of, M... and more
Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Chronic Myeloid Leukemia

France, United States, Spain, Belgium, Singapore, Poland, Canada, Japan, United Kingdom, Taiwan, Hungary, Germany, Argentina, Russian Federation, Turkey, Colombia, Italy, South Africa, Brazil, Chile, China, Hong Kong, India, Korea, Republic... and more
Mela Osorio Maria Jose
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia

CLL

Argentina
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
Boehringer Ingelheim

Completed

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Leukemia, Myeloid, Acute

Korea, Republic of, Spain, Canada, Germany, Norway, Taiwan, Belgium, United States, Japan, Mexico, France, Greece, Italy, India, Austria, Portugal, Czechia, Russian Federation, Hungary, Brazil, Argentina, Finland, Netherlands, Poland, South...
Helsinn Healthcare SA
Clinipace Worldwide

Terminated

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Spain, Australia, Taiwan, France, Italy, United Kingdom, Korea, Republic of, Argentina, Austria, Brazil, Czechia, Germany, Hungary, Poland, Romania
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
Hoffmann-La Roche

Completed

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Argentina, Venezuela
Novartis Pharmaceuticals

Completed

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States, Spain, Belgium, Germany, Japan, Taiwan, Turkey, Italy, Australia, Austria, Switzerland, Israel, Bulgaria, France, Norway, Brazil, Poland, Portugal, Czechia, Argentina
Daiichi Sankyo, Inc.

Completed

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

Acute Myeloid Leukemia | Leukemia

Hong Kong, Canada, Belgium, France, Spain, Taiwan, United States, Australia, Czechia, Hungary, Italy, Israel, Japan, Korea, Republic of, Germany, China, Ukraine, Romania, Argentina, Croatia, Brazil, Serbia, Russian Federation, Portugal, Bulgari... and more
Novartis Pharmaceuticals

Recruiting

Asciminib Roll-over Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myelogenous Leukemia

Denmark, Spain, France, Germany, Lebanon, Italy, Argentina, Czechia, Portugal, United Kingdom, Brazil, Mexico, Russian Federation, Taiwan, Austria, Canada, Korea, Republic of, Turkey, United States, Singapore, Japan, Bulgaria, Poland, Romani... and more
Sanofi

Terminated

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

France, Korea, Republic of, Mexico, Denmark, Norway, United States, Argentina, Brazil, Germany, Greece, Hungary, Italy, Netherlands, Peru, Portugal, Sweden
Novartis Pharmaceuticals

Active, not recruiting

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)

Chronic Myelogenous Leukemia

Belgium, Spain, Austria, Germany, Italy, France, Netherlands, Sweden, Japan, United States, Greece, United Kingdom, Bulgaria, Hungary, Argentina, Poland, Colombia, Ireland, Denmark
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
Antisoma Research

Unknown

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
Novartis Pharmaceuticals

Terminated

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG)

Leukaemia, Lymphocytic, Chronic

Belgium, Netherlands, United States, Argentina, Czechia, Denmark, France, Greece, Israel, Russian Federation, Sweden, Korea, Republic of, Australia, Brazil, Canada, Italy, Spain, Turkey, Hungary, Finland, Poland, Ukraine, Puerto Rico, Indi... and more
Novartis Pharmaceuticals

Completed

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (ASPIRE)

Thrombocytopaenia

United States, Belgium, Canada, Hong Kong, Argentina, Brazil, Czechia, Germany, Greece, Israel, Netherlands, Spain, Thailand, Hungary, Ireland, Italy, Mexico, Taiwan, Korea, Republic of, Poland, Russian Federation, Puerto Rico
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
Eisai Inc.

Completed

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic

Canada, Australia, United States, Argentina, Brazil
Asana BioSciences

Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Cancer | Lymphoma, Malignant | Myelofibrosis | Lymphoma, Mantle-Cell | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Tumor | Neoplasm | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | Idiopathic Myelofibrosis and other conditions

United States, Argentina
AstraZeneca

Completed

Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia (CREEK)

Chronic Lymphocytic Leukemia

Malaysia, Saudi Arabia, India, Mexico, Brazil, Singapore, Egypt, Taiwan, Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Kuwait, Panama, Turkey, United Arab Emirates
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia, Belgium
Leukemia Research Fund
Medical Research Council

Completed

Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Leukemia

United Kingdom, Italy, New Zealand, Ireland, Croatia, Russian Federation, Greece, Argentina
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Non-Hodgkins Lymphoma | Hematologic Malignancies | Chronic Lymphocytic Leukaemia | Waldenstroms Macroglobulinaemia

Poland, United States, Argentina, Australia, Brazil, Canada, France, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom, Korea, Republic of, Germany, Denmark, China, Romania, Czechia, Hungary, Ireland, Ukraine
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Australia, Brazil, Spain, Italy, Canada, Germany, Chile, Mexico, France, Argentina, Croatia, Russian Federation, Slovakia, Turkey, Poland, Czechia, New Zealand, Portugal, Greece
Hoffmann-La Roche

Completed

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Italy, Sweden, Belgium, Brazil, Canada, Germany, Ireland, Korea, Republic of, Spain, Russian Federation, France, Finland, Israel, Estonia, Romania, Egypt, Thailand, Switzerland, Bosnia and Herzegovina, Slovakia, Turkey, Lithuania, P... and more

Clinical Trials on Leukemia, Myeloid, Chronic-Phase in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations